Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 142

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

Brachmann, Rainer K., Yu, Kexin, Eby, Yolanda, Pavletich, Nikola P., Boeke, Jef D.·1998·The EMBO Journal
DOI 10.1093/emboj/17.7.1847
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/emboj/17.7.1847

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 57

  1. Abarzua P, LoSardo JE, Gubler ML and Neri A (1995) Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res, 55, 3490–3494.
  2. Abarzua P, LoSardo JE, Gubler ML, Spathis R, Lu YA, Felix A and Neri A (1996) Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene, 13, 2477–2482.
  3. Abraham DJ, Wireko FC, Randad RS, Poyart C, Kister J, Bohn B, Liard JF and Kunert MP (1992) Allosteric modifiers of hemoglobin: 2‐[4‐[[(3,5‐disubstituted anilino)carbonyl]methyl]phenoxy]‐2‐methyl‐ propionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry, 31, 9141–9149. · DOI
  4. Bae I, Smith ML, Sheikh MS, Zhan Q, Scudiero DA, Friend SH, O'Connor PM and Fornace AJJr (1996) An abnormality in the p53 pathway following gamma‐irradiation in many wild‐type p53 human melanoma lines. Cancer Res, 56, 840–847.
  5. Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild‐type p53. Science, 249, 912–915. · DOI · Paper page
  6. Bergh J, Norberg T, Sjogren S, Lindgren A and Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med, 1, 1029–1034. · DOI · Paper page
  7. Brachmann RK, Vidal M and Boeke JD (1996) Dominant‐negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA, 93, 4091–4095. · DOI
  8. Caelles C, Helmberg A and Karin M (1994) p53‐dependent apoptosis in the absence of transcriptional activation of p53‐target genes. Nature, 370, 220–223. · DOI · Paper page
  9. Cariello NF, Douglas GR and Soussi T (1996) Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents. Nucleic Acids Res, 24, 119–120. · DOI
  10. Caron de Fromentel C and Soussi T (1992) TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer, 4, 1–15. · DOI · Paper page
  11. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH (1993) Thymocyte apoptosis induced by p53‐dependent and independent pathways. Nature, 362, 849–852. · DOI · Paper page
  12. Donehower LA and Bradley A (1993) The tumor suppressor p53. Biochim Biophys Acta, 1155, 181–205.
  13. el‐Deiry WS et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817–825. · DOI · Paper page
  14. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell, 78, 539–542. · DOI · Paper page
  15. Freeman J, Schmidt S, Scharer E and Iggo R (1994) Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO J, 13, 5393–5400. · DOI
  16. Gibbs JB and Oliff A (1994) Pharmaceutical research in molecular oncology. Cell, 79, 193–198. · DOI
  17. Gorman CM, Geis DR and McCray G (1990) Transient production of proteins using an adenovirus transformed cell line. DNA Protein Eng Tech, 2, 3–10.
  18. Gottlieb TM and Oren M (1996) p53 in growth control and neoplasia. Biochim Biophys Acta, 1287, 77–102.
  19. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 54, 4855–4878.
  20. Haffner R and Oren M (1995) Biochemical properties and biological effects of p53. Curr Opin Genet Dev, 5, 84–90. · DOI
  21. Halazonetis TD and Kandil AN (1993) Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J, 12, 5057–5064. · DOI · Paper page
  22. Hann BC and Lane DP (1995) The dominating effect of mutant p53. Nature Genet, 9, 221–222. · DOI
  23. Hansen R and Oren M (1997) p53; from inductive signal to cellular effect. Curr Opin Genet Dev, 7, 46–51. · DOI · Paper page
  24. Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst, 88, 1442–1454. · DOI · Paper page
  25. Harris CC and Hollstein M (1993) Clinical implications of the p53 tumor‐suppressor gene. N Engl J Med, 329, 1318–1327. · DOI · Paper page
  26. Haupt Y, Rowan S, Shaulian E, Vousden KH and Oren M (1995) Induction of apoptosis in HeLa cells by trans‐activation‐deficient p53. Genes Dev, 9, 2170–2183. · DOI · Paper page
  27. Higuchi R, Krummel B and Saiki RK (1988) A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res, 16, 7351–7367. · DOI · Paper page
  28. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R and Harris CC (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res, 24, 141–146. · DOI · Paper page
  29. Hupp TR, Meek DW, Midgley CA and Lane DP (1993) Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res, 21, 3167–3174. · DOI · Paper page
  30. Hupp TR, Sparks A and Lane DP (1995) Small peptides activate the latent sequence‐specific DNA binding function of p53. Cell, 83, 237–245. · DOI · Paper page
  31. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B (1992) Oncogenic forms of p53 inhibit p53‐regulated gene expression. Science, 256, 827–830. · doi:10.1126/science.256.5058.827 · Paper page
  32. Kinzler KW and Vogelstein B (1994) Cancer therapy meets p53. N Engl J Med, 331, 49–50. · doi:10.1056/nejm199407073310113
  33. Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes Dev, 10, 1054–1072. · DOI · Paper page
  34. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323–331. · DOI · Paper page
  35. Lowe SW (1995) Cancer therapy and p53. Curr Opin Oncol, 7, 547–553. · DOI
  36. Lowe SW, Ruley HE, Jacks T and Housman DE (1993a) p53‐dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957–967. · DOI · Paper page
  37. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807–810. · DOI · Paper page
  38. Michalovitz D, Halevy O and Oren M (1991) p53 mutations: gains or losses? J Cell Biochem, 45, 22–29. · DOI
  39. Milner J (1995) DNA damage, p53 and anticancer therapies. Nature Med, 1, 879–880. · DOI
  40. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C and Kelly JW (1996) Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA, 93, 15051–15056. · DOI · Paper page
  41. Miura M, Zhu H, Rotello R, Hartwieg EA and Yuan J (1993) Induction of apoptosis in fibroblasts by IL‐1 beta‐converting enzyme, a mammalian homolog of the C. elegans cell death gene ced‐3. Cell, 75, 653–660. · DOI · Paper page
  42. Muhlrad D, Hunter R and Parker R (1992) A rapid method for localized mutagenesis of yeast genes. Yeast, 8, 79–82. · DOI · Paper page
  43. Neil JC, Cameron ER and Baxter EW (1997) p53 and tumour viruses: catching the guardian off‐guard. Trends Microbiol, 5, 115–120. · DOI
  44. Niewolik D, Vojtesek B and Kovarik J (1995) p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene, 10, 881–890.
  45. Pietenpol JA, Tokino T, Thiagalingam S el‐Deiry WS Kinzler KW and Vogelstein B (1994) Sequence‐specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA, 91, 1998–2002. · DOI · Paper page
  46. Redston MS et al. (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res, 54, 3025–3033.
  47. Robzyk K and Kassir Y (1992) A simple and highly efficient procedure for rescuing autonomous plasmids from yeast. Nucleic Acids Res, 20, 3790 · DOI · Paper page
  48. Roth JA et al. (1996) Retrovirus‐mediated wild‐type p53 gene transfer to tumors of patients with lung cancer (see comments). Nature Med, 2, 985–991. · DOI · Paper page
  49. Scharer E and Iggo RD (1992) Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res, 11, 1539–1545. · DOI · Paper page
  50. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC and Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C‐terminal domain. Nature Med, 3, 632–638. · DOI · Paper page
  51. Shortle D and Lin B (1985) Genetic analysis of staphylococcal nuclease: identification of three intragenic ‘global’ suppressors of nuclease‐minus mutations. Genetics, 110, 539–555. · DOI · Paper page
  52. Sikorski RS and Hieter P (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics, 122, 19–27. · DOI · Paper page
  53. Stratton MR et al. (1990) Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene, 5, 1297–1301.
  54. Vidal M, Brachmann RK, Fattaey A, Harlow E and Boeke JD (1996) Reverse two‐hybrid and one‐hybrid systems to detect dissociation of protein–protein and DNA–protein interactions. Proc Natl Acad Sci USA, 93, 10315–10320. · DOI · Paper page
  55. Vogelstein B and Kinzler KW (1992) p53 function and dysfunction. Cell, 70, 523–526. · DOI · Paper page
  56. White E (1996) Life, death, and the pursuit of apoptosis. Genes Dev, 10, 1–15. · DOI · Paper page
  57. Wieczorek AM, Waterman JL, Waterman MJ and Halazonetis TD (1996) Structure‐based rescue of common tumor‐derived p53 mutants. Nature Med, 2, 1143–1146. · DOI

Cited by

See all 142

Metadata

Authors
Brachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P., & Boeke, J. D.
Venue
The EMBO Journal
Publisher
Springer Science and Business Media LLC
Published
1998-04-01
Volume
17
Issue
7
Pages
1847-1859
ISSN
  • 0261-4189
  • 1460-2075
DOI
10.1093/emboj/17.7.1847
Cited by
142
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. https://app.cochat.ai/papers/10.1093/emboj/17.7.1847
The paper
Brachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P., & Boeke, J. D. (1998). Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. The EMBO Journal. https://doi.org/10.1093/emboj/17.7.1847

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.